Alpha Centric Advisors LLC Argenx Se Transaction History
Alpha Centric Advisors LLC
- $118 Million
- Q3 2024
A detailed history of Alpha Centric Advisors LLC transactions in Argenx Se stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 4,500 shares of ARGX stock, worth $2.93 Million. This represents 2.06% of its overall portfolio holdings.
Number of Shares
4,500
Previous 7,250
37.93%
Holding current value
$2.93 Million
Previous $3.12 Million
21.72%
% of portfolio
2.06%
Previous 2.57%
Shares
9 transactions
Others Institutions Holding ARGX
# of Institutions
404Shares Held
30.8MCall Options Held
376KPut Options Held
489K-
Price T Rowe Associates Inc Baltimore, MD5.82MShares$3.8 Billion0.36% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$2.29 Billion2.99% of portfolio
-
Janus Henderson Group PLC London, X02.48MShares$1.62 Billion0.72% of portfolio
-
Capital World Investors Los Angeles, CA1.7MShares$1.11 Billion0.15% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$808 Million10.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $36.1B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...